Cargando…
Dendritic cell-based immunotherapy in ovarian cancer
Worldwide, 80% of patients with ovarian cancer die of the disease. New treatments for this aggressive disease are therefore being intensively searched. Although dendritic cell-based vaccines against gynecological malignancies are in their infancy, this immunotherapeutic approach holds much promise....
Autores principales: | Coosemans, An, Vergote, Ignace, Van Gool, Stefaan W |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913669/ https://www.ncbi.nlm.nih.gov/pubmed/24501688 http://dx.doi.org/10.4161/onci.27059 |
Ejemplares similares
-
Targeting dendritic cells in situ for breast cancer immunotherapy
por: Wang, Bei
Publicado: (2012) -
Importance of helper T-cell activation in dendritic cell-based anticancer immunotherapy
por: Schreibelt, Gerty, et al.
Publicado: (2013) -
A critical role for natural killer cells in dendritic cell-based anticancer immunotherapy
por: McLellan, Alexander D
Publicado: (2014) -
Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosis
por: Labidi-Galy, Sana Intidhar, et al.
Publicado: (2012) -
A view on dendritic cell immunotherapy in ovarian cancer: how far have we come?
por: Coosemans, A., et al.
Publicado: (2015)